



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 7 August 2017 (#28)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries cdevries@sun.ac.za) to inform of your intent to apply.

Timelines:

Confirm your intent to apply **as soon as possible, but not later than 30 days** before the submission date.

All final documents **MUST reach the RGMO seven (7) workdays** before NIH application due date.

The application will be submitted **four (4) workdays** before the application due date.

Important Notices

- Updated Appendix Policy Eliminates Clinical Trial-Related Materials for NIH/AHRQ/NIOSH Applications Submitted to Due Dates on or After January 25, 2018 ([NOT-OD-17-098](#))
- NICHD Policy on Receipt of Investigator-Initiated Clinical Trials ([NOT-HD-17-019](#))
- Notice of Intent to Renew a Funding Opportunity Announcement for Autoimmunity Centers of Excellence (ACE) Clinical Research Program (UM1) ([NOT-AI-17-033](#))
- Notice of Correction in Expiration Date for PAR-17-331 "Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)" ([NOT-CA-17-075](#))
- Notice of Correction in Expiration Date for PA-17-330 "Using Small Molecules and Molecular Genetics to Identify Novel Targets and Mechanisms Contributing to Tumor Immune Evasion (R01)" ([NOT-CA-17-076](#))
- Notice of Change to Expiration Date and Award Information in PAR-17-334 "Synthetic Biology for Engineering Applications (R01)" ([NOT-EB-17-007](#))
- Notice of Withdrawal from participation in PA-16-161 "NIH Exploratory/Developmental Research Grant Program (Parent R21)" ([NOT-EB-17-008](#))
- Notice of Withdrawal from participation in PA-16-040 "Exploratory/Developmental Bioengineering Research Grants (EBRG)(R21)" ([NOT-EB-17-009](#))

1. Pharmacogenomics of Anti-retroviral Therapy in People Who Inject Drugs

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([RFA-DA-18-014](#))

Type: R01

Application Due Date: 14 Dec 2017 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity is to identify genetic and epigenetic factors that affect the recovery of the CD4+ T cells in response to anti-retroviral therapy in HIV infected people who inject drugs.

Budget: NIDA intends to fund an estimate of 1 to 2 awards, corresponding to a total of \$3,000,000 for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. Application budgets may not exceed \$2,000,000 in direct cost. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. HIV-associated neuropathic pain and opioid interaction

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([RFA-DA-18-015](#))

Type: R01

Application Due Date: 18 Dec 2017 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this RFA is to promote research investigating the underlying mechanisms by which opioids including prescription drugs exacerbate HIV-associated neuropathic pain. Results from these studies may help obtain information for developing safe and effective treatments of neuropathic pain for HIV-infected patients exposed to opioids.

Budget: NIDA intends to fund an estimate of 4-5 grant awards, corresponding to a total of \$3 M for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The direct cost of an application must be less than \$500,000. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([PA-17-440](#))

Type: R01

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naïve and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving naïve and drug resistant cancer cells toward effective cell death.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The total project period may not exceed 5 years.

4. Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([PA-17-444](#))

Type: R01

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years, but given how quickly the field is evolving, it is expected that many projects will be no more than 3 years in duration. Longer project periods should be well justified. Additional consideration for longer projects may be given to new or early stage investigators. All applicants are strongly encouraged to discuss project length with Scientific/Research Staff prior to submission.

5. Ethical, Legal, and Social Implications (ELSI) of Genomics Small Research Grant Program

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([PA-17-445](#))

Type: R03

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

Budget: Application budgets are limited to no more than \$50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

6. Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([PA-17-446](#))

Type: R21

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Budget: Application budgets are limited to a combined total of no more than \$275,000 in direct costs for the two year project, with no more than \$200,000 in direct costs in a single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

7. The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-17-449\)](#)

Type: R21

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naïve and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving naïve and drug resistant cancer cells toward effective cell death.

Budget: Direct costs are limited to \$275,000 over a two-year project period, with no more than \$200,000 in direct costs allowed in any single year. The maximum project period is 2 years.

8. Pregnancy in Women with Disabilities

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-17-452\)](#)

Type: R01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement This funding opportunity announcement (FOA) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Applicants are encouraged to include women with disabilities and members of the community in the design and conduct of their research.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

9. Pregnancy in Women with Disabilities

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-17-451\)](#)

Type: R03

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement This funding opportunity announcement (FOA) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages small research project grants (R03) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Applicants are encouraged to include women with disabilities and members of the community in the design and conduct of their research.

Budget: Application budgets are limited to \$50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is two years.

10. National Institute of Biomedical Imaging and Bioengineering (NIBIB) Exploratory/Developmental Research Grant Program

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-17-441\)](#)

Type: R21

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. ****This FOA is being issued with limited due dates to accommodate the transition from FORMS-D to FORMS-E application packages. This FOA will be reissued for additional due date(s) on or after 25 January 2018.****

This Funding Opportunity Announcement This FOA will support exploratory/developmental research programs of interest to the NIBIB (<https://www.nibib.nih.gov/research-funding>). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.

Budget: Application budgets may not exceed \$275,000 direct costs over a maximum two-year funding period. No more than \$200,000 in direct costs may be requested in any single year. The total project period may not exceed 2 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).